Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$11.09 +1.4%	$10.08	$8.06 ▼ $16.50	$146.25M	1.65	77,471 shs	45,636 shs
MRVI Maravai LifeSciences	$2.22 -5.1%	$2.40	$1.66 ▼ $9.95	$595.90M	0.28	1.51 million shs	1.18 million shs
PRME Prime Medicine	$4.04 +8.0%	$2.82	$1.11 ▼ $5.18	$543.36M	2.33	2.39 million shs	4.71 million shs
RLAY Relay Therapeutics	$3.36 -4.5%	$3.42	$1.77 ▼ $10.72	$603.49M	1.62	2.64 million shs	2.79 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	+1.37%	-4.15%	+12.25%	+11.01%	-31.20%
MRVI Maravai LifeSciences	-5.13%	-17.47%	-16.23%	+7.25%	-77.18%
PRME Prime Medicine	+8.02%	-4.04%	+31.60%	+140.48%	-27.99%
RLAY Relay Therapeutics	-4.55%	-10.16%	-6.67%	+3.38%	-59.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLSI Greenwich LifeSciences	1.3032 of 5 stars	3.5	1.0	0.0	0.6	1.7	0.0
MRVI Maravai LifeSciences	3.7372 of 5 stars	3.1	1.0	4.4	2.7	0.8	1.3
PRME Prime Medicine	3.7286 of 5 stars	4.4	1.0	0.0	3.0	5.0	0.6
RLAY Relay Therapeutics	1.9412 of 5 stars	3.4	0.0	0.0	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	251.67% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	199.05% Upside
PRME Prime Medicine	2.75	Moderate Buy	$9.25	128.96% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	425.79% Upside

Current Analyst Ratings Breakdown

Latest GLSI, MRVI, PRME, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
MRVI Maravai LifeSciences	$259.18M	2.18	$0.59 per share	3.79	$2.28 per share	0.97
PRME Prime Medicine	$3.85M	141.28	N/A	N/A	$1.37 per share	2.95
RLAY Relay Therapeutics	$10.01M	57.55	N/A	N/A	$4.65 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/13/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/11/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/7/2025 (Estimated)

Latest GLSI, MRVI, PRME, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GLSI Greenwich LifeSciences	-$0.24	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	MRVI Maravai LifeSciences	-$0.06	N/A	N/A	N/A	$47.46 million	N/A
8/7/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	35.79%	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLSI Greenwich LifeSciences	N/A	1.91	1.91
MRVI Maravai LifeSciences	0.60	5.96	5.17
PRME Prime Medicine	N/A	6.50	6.50
RLAY Relay Therapeutics	N/A	19.96	19.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLSI Greenwich LifeSciences	4.16%
MRVI Maravai LifeSciences	50.25%
PRME Prime Medicine	70.37%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
GLSI Greenwich LifeSciences	51.67%
MRVI Maravai LifeSciences	2.11%
PRME Prime Medicine	22.74%
RLAY Relay Therapeutics	4.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
PRME Prime Medicine	234	134.50 million	100.38 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable

GLSI, MRVI, PRME, and RLAY Headlines

Recent News About These Companies

Brokerages Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $17.67

1 hour ago | americanbankingnews.com

Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)

August 1 at 2:18 AM | msn.com

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 4,069 Shares of Stock

July 31 at 8:04 PM | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 15,724 Shares

July 31 at 8:04 PM | marketbeat.com

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 18,276 Shares of Stock

July 31 at 8:03 PM | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 18,380 Shares

July 31 at 8:03 PM | marketbeat.com

Donald A. Bergstrom Sells 26,701 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

July 31 at 7:37 PM | marketbeat.com

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

July 31 at 4:05 PM | globenewswire.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $15,218.06 in Stock

July 31 at 7:01 AM | insidertrades.com

Relay Therapeutics (RLAY) to Release Quarterly Earnings on Tuesday

July 30 at 8:18 AM | marketbeat.com

Relay Therapeutics has positive read from Celcuity data, says Barclays

July 30 at 7:30 AM | finance.yahoo.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Analysts

July 30 at 2:45 AM | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Sees Large Volume Increase - Still a Buy?

July 25, 2025 | marketbeat.com

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

July 25, 2025 | zacks.com

Relay Therapeutics (NASDAQ:RLAY) Shares Up 5.6% - Should You Buy?

July 16, 2025 | marketbeat.com

Private Capital Advisors Inc. Acquires Shares of 100,000 Relay Therapeutics, Inc. (NASDAQ:RLAY)

July 14, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 61,379 Shares

July 11, 2025 | insidertrades.com

Sanjiv Patel Sells 61,379 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

July 10, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT

June 24, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI, MRVI, PRME, and RLAY Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

$11.09 +0.15 (+1.37%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.95 -0.14 (-1.26%)

As of 08/1/2025 04:12 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Maravai LifeSciences NASDAQ:MRVI

$2.22 -0.12 (-5.13%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.00 (+0.23%)

As of 08/1/2025 07:19 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Prime Medicine NYSE:PRME

$4.04 +0.30 (+8.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.34 +0.30 (+7.33%)

As of 08/1/2025 07:57 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Relay Therapeutics NASDAQ:RLAY

$3.36 -0.16 (-4.55%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.36 0.00 (0.00%)

As of 08/1/2025 07:10 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time